NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
    Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
    India

    Government expert panel recommends conducting trials on mixing Covishield, COVAXIN

    Written by Ramya Patelkhana
    July 30, 2021 | 11:33 am 3 min read
    Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
    COVID-19 vaccine cocktail: Expert panel gives nod for study on mixing Covishield, COVAXIN doses

    The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses. The expert panel on Thursday recommended granting permission to the Christian Medical College (CMC), Vellore in Tamil Nadu for carrying out the trials on mixing of these vaccine doses.

    It will be India's first ever mix-and-match vaccine study

    The SEC, amid increasing discussions on the supposed greater efficacy of mixing different COVID-19 vaccines, deliberated in detail on the application moved by CMC, Vellore for trials on the interchangeability of Covishield and COVAXIN doses. This will be India's first-ever mix-and-match study involving the two vaccines. The SEC met on Thursday to discuss issues concerning the updating of the current COVID-19 protocol being followed.

    The study will be conducted on 300 healthy volunteers

    "The expert panel discussed a study protocol by CMC, Vellore for interchangeability of COVAXIN and Covishield vaccines and gave its green signal," said a senior government official. The trials will be reportedly conducted among 300 volunteers—split into two groups. While the first group takes Covishield as the first dose and COVAXIN as the second, the other group will receive COVAXIN first and Covishield later.

    Aim is to assess whether one can take different shots

    "The SEC, after detailed deliberations, recommended granting permission to CMC, Vellore, for conducting the phase-4 clinical trial covering 300 healthy volunteers for mixing of COVID-19 vaccines COVAXIN and Covishield," a source told India.com. "The aim of the study is to assess whether a person can be given two different vaccine shots—one each of Covishield and COVAXIN—to complete the inoculation course," the source said.

    What do the experts say about this mix-and-match strategy?

    The mix-and-match of COVID-19 vaccines is a method of immunization involving the administration of two doses from different makers. Many experts believe giving two vaccines developed on different platforms would produce a better immune response, offering greater protection against COVID-19. However, some feel it's not a good idea as these vaccines are manufactured differently and the end result may not really be favorable.

    The homologous and heterologous prime-boost immunization strategies

    This mix-and-match vaccination strategy is called heterologous prime-boost immunization, which has reportedly been used in vaccine development to fight Ebola and experimental vaccines for HIV/AIDS, too. Traditionally, however, homologous prime-boost vaccination, involving the administration of doses of the same vaccine, is followed. But some studies have shown that prime-boost with different jabs comprising the same antigens could trigger better immune responses than homologous prime-boost.

    Covishield and COVAXIN are based on different vaccine platforms

    To note, Covishield—based on the viral vector platform—has been developed by Oxford-AstraZeneca and is manufactured by Pune-based Serum Institute of India (SII). COVAXIN—based on inactivated whole virion platform—has been developed by Hyderabad-based Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR). Covishield, COVAXIN, and Russia's Sputnik V are the vaccines currently being administered as part of India's vaccination drive.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Central Drugs Standard Control Organization (CDSCO)
    Christian Medical College
    COVID-19
    COVID-19 Vaccine
    COVAXIN

    Central Drugs Standard Control Organization (CDSCO)

    Expert panel says no to Covovax's children trials in India Drugs Controller General of India
    COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel Vaccine
    Foreign COVID-19 vaccines: Decision on EUA applications within three days Coronavirus
    Panel recommends permission for Phase I Intranasal COVID-19 vaccine trial Drugs Controller General of India

    Christian Medical College

    Vaccine expected by early 2021; nationwide immunization a challenge: Scientist Vaccine
    #CareerBytes: 7 top-rated medical colleges for undergraduate courses in India India
    #CareerBytes: Top career options for PCB students after Class 12 Bengaluru

    COVID-19

    China sees new COVID-19 outbreaks as Delta variant takes hold China
    Mumbai: Local trains might be opened for fully vaccinated individuals Mumbai
    Kerala imposes complete weekend lockdown following spike in COVID-19 cases Kerala
    Coronavirus: India reports 43K+ cases; Kerala orders weekend lockdown Kerala

    COVID-19 Vaccine

    Government trashes reports on missing July-end target of vaccine administration Ministry of Health and Family Welfare
    European drug regulator approves Moderna COVID-19 vaccine, Spikevax, for 12-17-year-olds Europe
    COVID-19 vaccination drive to resume from Friday in Mumbai Mumbai
    Coronavirus: India adds 4,000 more deaths as Maharashtra clears backlog Maharashtra

    COVAXIN

    As vaccination pace remains slow, Centre may reduce private quota Coronavirus
    India to miss July vaccination target over low COVAXIN supply Health & Wellness
    Bharat Biotech ends its Brazil agreement. What went wrong? Brazil
    COVID-19 vaccines for children likely by September, says AIIMS chief Randeep Guleria
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023